Inovio Hpv Cure









All the 148 women enrolled in the Inovio phase II study are confirmed positive for the human papillomavirus (HPV) serotypes 16 and 18, and have a baseline diagnosis of CIN grades 2 or 3, meaning. Inovio is studying INO-1307 for its ability to treat Recurrent Respiratory Papllomatosis (RPP). METHODS: Efficacy, safety, and immunogenicity of VGX-3100 were assessed in CIN2/3 associated with HPV-16 and HPV-18, in a randomised, double-blind, placebo-controlled phase 2b study. Putting aside INO-4800, Inovio's next most promising vaccine is VGX-3100, which treats pre-cancerous cells (lesions) found in certain strains of human papillomavirus (HPV). Also in development are Phase 2 immuno-oncology programs targeting HPV-related cancers and glioblastoma, as well as externally funded platform development programs in Zika, MERS, Lassa and HIV. VGX-3100 is being assessed as an alternative to surgery with the potential to clear the underlying HPV infection. While Inovio is attempting to capitalize on the need for a coronavirus treatment, there's more to its story. The regulatory body’s acceptance allows the company to begin a phase I/II study to evaluate the candidate for the treatment of patients with recurrent respiratory papillomatosis (RRP), a rare disease caused by certain types of HPV. HPV is most common in people in their late teens and early 20s. Description. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. He noted along with the research Medimmune is doing with HPV-related cancer, Inovio's VGX-3100 is currently being tested in global phase-III pivotal trials for cervical pre-cancer as well as a. (NASDAQ: INO) made waves early on Tuesday morning following an update for its human papillomavirus (HPV) treatment. 15 billion by 2026, exhibiting a CAGR of 16. Inovio is a biotech company specializing in medicines that treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. Inovio conducts a pivotal phase III REVEAL program to evaluate the safety and efficacy of VGX-3100 for the treatment of cervical dysplasia caused by human papillomavirus (HPV). , June 26, 2019 PLYMOUTH MEETING, Pa. Inovio’s VGX-3100 is designed to raise immune responses against the E6 and E7 genes common to HPV types 16 and 18 that are present in both pre-cancerous and cancerous cells transformed by these. But if it doesn't go away by itself, and if. Human papillomavirus vaccines have widely applauded as a sweeping vaccine innovation for the universal benefit of all the women and girls. Inovio purports to be a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure and/or protect people from diseases associated with human. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body. INOVIO has worked with Richter-Helm since 2014 on the manufacturing of VGX-3100, our Phase 3 clinical trial candidate for the treatment of precancerous cervical dysplasia caused by high-risk HPV. INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and. Inovio is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body. INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious. The global human papillomavirus (HPV) vaccines market size was USD 3. Putting aside INO-4800, Inovio's next most promising vaccine is VGX-3100, which treats pre-cancerous cells (lesions) found in certain strains of human papillomavirus (HPV). (RTTNews) - INOVIO Pharmaceuticals, Inc. This is targeted at HPV, which is a virus that can lead to cervical cancer. Under the agreement, MedImmune will acquire exclusive rights to Inovio's INO-3112 immunotherapy, which targets cancers caused by human papillomavirus (HPV) types 16 and 18. Inovio’s Phase 2 immuno-oncology program targets glioblastoma and other HPV-related cancers. Inovio's SynCon(TM) Universal Influenza DNA Vaccine Technology Recognized with NIH Director's Transformative Research AwardInovio and University of Pennsylvania Awarded $3. Background: Recurrent respiratory papillomatosis (RRP) is a rare disorder characterized by the generation of papillomas of the aerodigestive tract, usually associated with human papilloma virus (HPV) subtypes 6, 11. Better Coronavirus Stock: Gilead Sciences vs. View Bridgette White's business profile as Senior Clinical Program Manager at Inovio Pharmaceuticals , Inc. Also in development are Phase 2 immuno-oncology programs targeting HPV-related cancers, bladder cancer, and glioblastoma, as well as platform development programs in hepatitis B, Zika, Ebola, MERS, and HIV. News Cervical Cancer Screening Device Mía, by Mel-Mont Medical, Allows HPV Sampling at Home News Cervical Cancer Patient Achieves Long-lasting Response to AXAL in Clinical Trial News 2 Doses of HPV Vaccine Protect Against Genital Warts, Study Finds, But Impact on Cancer Unknown. The study will assess the efficacy and safety of VGX-3100 in 24 adult men and women with anal high-grade squamous. Panel of health specialists is boosting guide for the hpv test as a recurring a part of cervical most cancers screening. VGX-3100 works by stimulating a specific immune response to HPV-16 and HPV-18, which targets the infection and causes destruction of precancerous cells. INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. Inovio plans to advance MEDI0457 (a combination of Inovio's VGX-3100 immunotherapy and a DNA-based immune activator encoded for IL-12) in combination with AstraZeneca's AZN checkpoint inhibitor for HPV-related cancers, including the phase II study to treat head and neck cancer. We want to own it from pre-cancers by ourselves to cancers with our partner MedImmune. PLYMOUTH MEETING, Pa. The consortium and Inovio will test an experimental immunotherapy in patients with HPV-related anal dysplasia or squamous intraepithelial lesions and HIV. (NASDAQ: INO) today announced that a second patient with HPV-related head and neck cancer treated with INO-3112. Putting aside INO-4800, Inovio's next most promising vaccine is VGX-3100, which treats pre-cancerous cells (lesions) found in certain strains of human papillomavirus (HPV). VGX-3100 is a therapeutic DNA vaccine being investigated for the treatment of pre-cancers and cancers such as cervical cancer, caused by the human papillomavirus (HPV) subtypes 16 and 18 (HPV-16 and HPV-18). Also in development are Phase 2 immuno-oncology programs targeting. "The data we collected from our phase II program points to a very interesting new approach to the treatment of HPV-related affections," stated Jean-Francois Carmier, Chief Executive Officer of Transgene. Anal dysplasia lesions can be removed through surgery, electro-cautery or laser therapy, but they recur in up to half of patients within one year of treatment, and nearly 70% have recurrences. VGX-3100 is injected by inserting the needle from the study device into the muscle of your upper arm (deltoid) or thigh (rarely). About VGX-3100 VGX-3100 is a DNA-based immunotherapy developed for HPV infection of the cervix and as the first non-surgical treatment for precancerous cervical lesions. Inovio Pharmaceuticals Inc. HPV is a serious problem. , a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Inovio is investigating VGX-3100, a DNA-based immunotherapy for the treatment of HPV-16 and HPV-18 infection and pre-cancerous lesions of the cervix (Phase 3) and vulva (Phase 2) and anal (Phase 2). Putting aside INO-4800, Inovio's next most promising vaccine is VGX-3100, which treats pre-cancerous cells (lesions) found in certain strains of human papillomavirus (HPV). INO Reports Positive Interim Data In Treatment Of HPV-Related Vulvar Dysplasia. 2 abbreviation for human parvovirus. According to the CDC, the body's immune system clears HPV from 90 percent of individuals who have it within two years. HPV vaccination protects against this virus and the cancers it can cause. INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. Inovio Pharmaceuticals a precancerous condition caused by human papillomavirus (HPV) types 16 and 18. Inovio Completes Enrollment of VGX-3100 Phase 3 Trial (REVEAL 1) for the Treatment of HPV-Related Cervical Pre-cancer News provided by Inovio Pharmaceuticals, Inc. Also in development are Phase 2 immuno-oncology programs targeting HPV-related cancers and GBM, as well as externally funded platform development programs in Zika, MERS, Lassa, and HIV. Inovio Receives European Medicines Agency Certification For Quality and Non-Clinical Data for Its Phase 3 Product, VGX-3100 for the treatment of HPV 16 and HPV 18 infection and precancerous. Twin Phase 3. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body. Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. "Inovio's investigational DNA medicine INO-3107 is designed to destroy and clear tumors caused by HPV 6 and 11 infections from the body exactly where they are hiding," said Jeffrey Skolnik, M. INO-3112 combines Inovio’s VGX-3100, its immunotherapy targeting HPV-caused diseases, with its DNA-based immune activator encoded for IL-12. , a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. PLYMOUTH MEETING, Pa. Vaccitech is a spin-out company from the University of Oxford’s Jenner Institute, one of the oldest and most renowned vaccine research centres in the world. VIN recurs in approximately one of every two patients who undergo surgical treatment. “Inovio’s primary goal is to become the global leader in HPV-related disease treatment," said Dr. Also in development are Phase 2 immuno-oncology programs targeting HPV-related cancers and glioblastoma, as well as externally funded platform development programs in Zika, MERS, Lassa and HIV. Inovio’s study will. Inovio Pharmaceuticals, Inc. Inovio's most advanced clinical program, VGX-3100, is in Phase 3 for the treatment of HPV-related cervical pre-cancer. HPV Antivirals Therapeutics Cures Vaccines - News and novelties - @worrymuch - Cervical cancer and HPV - 20150503. Top-line efficacy data from the REVEAL 1 program are. Also in development are Phase 2 immuno-oncology programs targeting HPV-related cancers and GBM, as well as externally funded vaccine development programs in Zika, MERS, Lassa, HIV, and the novel coronavirus (2019-nCoV). Inovio's current top ambition is to cover the pharmacologic treatment space for existing precancers and cancers caused by HPV. Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure and/or protect people from diseases associated with HPV, cancer, and. INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and. Inovio's most advanced clinical program, VGX-3100, is in Phase 3 development for the treatment of HPV-related cervical pre-cancer. Inovio to receive up to $50 million in upfront and near term payments and equity investment. It is being developed by Inovio Pharmaceuticals. Anal dysplasia lesions can be removed through surgery, electro-cautery or laser therapy, but they recur in up to half of patients within one year of treatment, and nearly 70% have recurrences. INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. VGX-3100 is a therapeutic DNA vaccine being investigated for the treatment of pre-cancers and cancers such as cervical cancer, caused by the human papillomavirus (HPV) subtypes 16 and 18 (HPV-16 and HPV-18). Cervical cancer prevention 10 weight loss program tips for inclined. Inovio Pharmaceuticals One biotech is developing a promising antiviral treatment for COVID-19. * inovio pharmaceuticals inc - on feb 7, co entered into an amendment to at-the-market equity offering sales agreement dated may 25, 2018 BRIEF-Inovio Opens Trial To Test Its VGX-3100 Drug In HPV. The Precision Medicine partnership focuses on Inovio's VGX-3100, a late-stage investigational product candidate with potential to become the first treatment for HPV infection of the cervix and the first non-surgical treatment for precancerous cervical lesions associated with the virus. The Principles of Journalism for the 21st century clearly state that journalism’s […]. MEDI0457 (previously called INO-3112) is an investigational immunotherapy being developed to treat human papillomavirus (HPV)-positive cervical cancer and head and neck cancer. Putting aside INO-4800, Inovio's next most promising vaccine is VGX-3100, which treats pre-cancerous cells (lesions) found in certain strains of human papillomavirus (HPV). Inovio Pharmaceuticals, Inc. Huh f Mark H. 5% 2024-03-01 Parkside Financial Bank & Trust ownership in INO / Inovio Pharmaceuticals, Inc. Background: Recurrent respiratory papillomatosis (RRP) is a rare disorder characterized by the generation of papillomas of the aerodigestive tract, usually associated with human papilloma virus (HPV) subtypes 6, 11. Inovio's most advanced clinical program, VGX-3100, is in Phase 3 development for the treatment of HPV-related cervical pre-cancer. Inovio started phase 3 program for VGX-3100 HPV immunotherapy in cervical pre-cancer in June 2017. Also in development are Phase 2 immuno-oncology programs targeting HPV-related cancers and glioblastoma, as well as externally funded platform development programs in Zika, MERS, Lassa and HIV. Revealing new treatment possibilities. 26, 2019, 09:11 AM. The Precision Medicine partnership focuses on Inovio's VGX-3100, a late-stage investigational product candidate with potential to become the first treatment for HPV infection of the cervix and. Meanwhile, to help Inovio develop a. Inovio is also evaluating VGX-3100 in two phase II studies for the treatment of anal dysplasia caused by human papillomavirus (HPV) and for vulvar dysplasia caused by HPV. If approved, it will be the first immunotherapy and a non-surgical treatment option for women with late-stage cervical dysplasia. INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and. VGX-3100 is currently being evaluated in a phase III study (REVEAL 1) for the treatment of cervical dysplasia caused by papillomavirus (HPV). Indeed, just last week, Inovio saw its stock surge after it showed for the first time that its therapeutic synthetic vaccine, VGX-3100, can kill cells changed by the human papillomavirus (HPV) into precancerous cervical dysplasias. Inovio is the first to demonstrate that DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. He noted along with the research Medimmune is doing with HPV-related cancer, Inovio’s VGX-3100 is currently being tested in global. (NASDAQ:INO). Inovio Completes Enrollment of VGX-3100 Phase 3 Trial (REVEAL 1) for the Treatment of HPV-Related Cervical Pre-cancer PR Newswire PLYMOUTH MEETING, Pa. Inovio Pharmaceuticals Inc, a biotechnology company, announced publication of data from its pilot clinical study of INO-3106, a novel DNA therapy targeting human papilloma virus type 6 (HPV 6) for the treatment of recurrent respiratory papillomatosis (RRP), a rare and orphan disease, in the open access scientific journal Vaccines (MDPI). VGX-3100, based on the company's SynCon technology, is an HPV-specific immunotherapy designed as a non-surgical treatment for high-grade cervical dysplasia and related underlying persistent HPV. Description. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body. There are more than 40 kinds of HPV and some strains of the virus can cause cervical cancer and other cancers such as penile or anal cancers. Inovio’s Phase 2 immuno-oncology program targets glioblastoma and other HPV-related cancers. An influential u. Our core focus continues to be on advancing our versatile HPV treatment capabilities that target HPV-related diseases which lack therapeutic alternatives to surgery, and we add to that our strategies to develop fast-to-market products like RRP. Inovio is also evaluating VGX-3100 in two phase II studies for the treatment of anal dysplasia caused by human papillomavirus (HPV) and for vulvar dysplasia caused by HPV. Einstein d 2 Francisco Garcia e 3 Warner K. Putting aside INO-4800, Inovio's next most promising vaccine is VGX-3100, which treats pre-cancerous cells (lesions) found in certain strains of human papillomavirus (HPV). The human papillomavirus, or HPV, can cause several cancers. VGX-3100 by Inovio is “an investigational DNA immunotherapy candidate designed to treat precancers and cancers caused by human papillomavirus (HPV). Inovio is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the. VGX-3100 has the potential to be the first approved treatment for HPV infection of the cervix and the first non-surgical treatment for pre. VGX-3100 is a therapeutic DNA vaccine being investigated for the treatment of pre-cancers and cancers such as cervical cancer, caused by the human papillomavirus (HPV) subtypes 16 and 18 (HPV-16 and HPV-18). Business World: Inovio Initiates REVEAL 2 Global Phase 3 Clinical Study For the Treatment of HPV-Related Cervical Pre-cancer - PLYMOUTH MEETING: Inovio Pharmaceuticals, Inc. This is targeted at HPV, which is a virus that can lead to cervical cancer. but they recur in up to half of patients within one year of treatment, and nearly 70%. HPV frequently. PLYMOUTH MEETING, Pa. VGX-3100, based on the company's SynCon technology, is an HPV-specific immunotherapy designed as a non-surgical treatment for high-grade cervical dysplasia and related underlying persistent HPV. (INO) has reported encouraging interim data from its phase II trial of VGX-3100 in women with vulvar dysplasia, also known as high grade squamous. no treatment, but a vaccine can More than 33,000 men and women. The vaccine, given by injection into the arm, is made by Inovio Pharmaceuticals Inc. , April 3, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. Treatment with VGX-3100, Inovio’s HPV16/18. VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2 - Full Text View. Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and. Inovio's study will. After all, Inovio has soared in the past on similar hopes that it could cure or provide a vaccine for dangerous viruses. skip to content Rare Cancer News & Clinical Trials » Google - Anal Cancer » Inovio Completes Enrollment of its VGX-3100 Open-label Phase 2 Trial for Treatment of HPV-Related High-Grade Anal Dysplasia - BioSpace. Its most advanced clinical program is VGX-3100. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body. The company is focused on rapidly bringing to market precisely designed and delivered DNA medicines to potentially treat and protect people from serious and life-threatening diseases associated with HPV, cancer, and infectious diseases. Inovio is investigating VGX-3100, a DNA-based immunotherapy for the treatment of HPV-16 and HPV-18 infection and pre-cancerous lesions of the cervix (Phase 3) and vulva (Phase 2) and anal (Phase 2). California-based Inovio Pharmaceuticals has licensed its pre-cancer human papilloma virus (HPV) immunotherapy to Chinese biomedical company ApolloBio. Inovio Pharmaceuticals, Inc. Inovio is studying INO-1307 for its ability to treat Recurrent Respiratory Papllomatosis (RPP). However, the goal of the HPV REVEAL 2 clinical study is to potentially provide a nonsurgical treatment alternative. Keep tabs on your portfolio, search for stocks, commodities, or mutual funds with screeners, customizable chart indicators and technical analysis. In a little over three months since trial initiation, Inovio has opened nearly 35 sites, recruiting and dosing patients. —Inovio Pharmaceuticals, Inc. Currently, VGX-3100 is in Phase 3 clinical trials for the treatment of precancerous cervical dysplasia caused by high-risk human papillomavirus (HPV). PLYMOUTH MEETING, Pa. gov NCT03180684: , for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous lntraepithelial Lesion (HSIL) of the Vulva. Putting aside INO-4800, Inovio's next most promising vaccine is VGX-3100, which treats pre-cancerous cells (lesions) found in certain strains of human papillomavirus (HPV). Study Start Date : April 2011: Actual Primary Completion Date : May 2014: Actual Study. INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to potentially treat and protect people from diseases associated with HPV, cancer, and infectious diseases. (INO) has reported encouraging interim data from its phase II trial of VGX-3100 in women with vulvar dysplasia, also known as high grade squamous. After all, Inovio has soared in the past on similar hopes that it could cure or provide a vaccine for dangerous viruses. HPV frequently. Inovio Pharmaceuticals, Inc. Inovio Partners with AIDS Malignancy Consortium to Advance Inovio’s HPV Therapy for High-Grade Anal Dysplasia in HIV-positive Patients October 13, 2017 AMC Fellowship Announcement. In June, Inovio commenced its phase 3 clinical program to evaluate the efficacy of Inovio’s DNA-based immunotherapy, VGX-3100, to treat cervical dysplasia caused by human papillomavirus (HPV). - VGX-3100 DNA medicine cleared high-risk HPV 16/18-associated precancerous lesions in 50% of patients, and reduced the number of lesions in 75% o. Get the facts on cervical cancer signs and symptoms, remedy, tiers, and causes (hpv or human papillomavirus). After I heard about my hpv i couldn’t live my normal life anymore. relevant relationships with Inovio Pharmaceuticals and Frantz Viral. After I heard about my hpv i couldn’t live my normal life anymore. Inovio Pharmaceuticals One biotech is developing a promising antiviral treatment for COVID-19. Currently, VGX-3100 is in Phase 3 clinical trials for the treatment of precancerous cervical dysplasia caused by high-risk human papillomavirus (HPV). Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. The regulatory body’s acceptance allows the company to begin a phase I/II study to evaluate INO-3107 for the treatment of patients with recurrent respiratory papillomatosis (RRP), a rare disease caused by certain types of human papillomavirus. View Bridgette White's business profile as Senior Clinical Program Manager at Inovio Pharmaceuticals , Inc. By Norma Erickson When it comes to the debate surrounding vaccine safety, efficacy and need, fair and balanced journalism may be a thing of the past. The article, entitled "Immune Therapy Targeting E6/E7 Oncogenes of Human Papillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis. , a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Study approximately cervical most cancers prognosis (extraordinary pap smear. Inovio Inks $35M Chinese Drug License Deal (INO) or preventing pre-cancerous HPV infections and HPV-driven dysplasias. VGX-3100 works by stimulating a specific immune response to HPV-16 and HPV-18, which targets the infection and causes destruction of precancerous cells. Einstein d 2 Francisco Garcia e 3 Warner K. The regulatory body’s acceptance allows the company to begin a phase I/II study to evaluate the candidate for the treatment of patients with recurrent respiratory papillomatosis (RRP), a rare disease caused by certain types of HPV. Inovio is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the. MY LIFE IS BACK, Am so happy to share this testimony on how Dr Unuareghe, was able to heal me from HpV Disease, well i was detected positive on 23th may 2015, and ever since i have been looking for a way to treat and cure this disease from me, but all ways i try there was no solution, few weeks ago i saw a testimony of some people on how Dr unureghe was able to cure them from HpV disease. (INO), a biotechnology company focused on rapidly brin. Business World: Inovio Initiates REVEAL 2 Global Phase 3 Clinical Study For the Treatment of HPV-Related Cervical Pre-cancer - PLYMOUTH MEETING: Inovio Pharmaceuticals, Inc. Its most advanced clinical program is VGX-3100. Inovio is also evaluating VGX-3100 in two phase II studies for the treatment of anal dysplasia caused by human papillomavirus (HPV) and for vulvar dysplasia caused by HPV. Inovio is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body. Inovio conducts a pivotal phase III REVEAL program to evaluate the safety and efficacy of VGX-3100 for the treatment of cervical dysplasia caused by human papillomavirus (HPV). Most notably, Inovio has an HPV (human papillomavirus)-related vaccine known as VGX-3100 that's currently in late-stage clinical testing with one stage 3 trial and two stage 2 trials ongoing. * inovio pharmaceuticals inc - on feb 7, co entered into an amendment to at-the-market equity offering sales agreement dated may 25, 2018 BRIEF-Inovio Opens Trial To Test Its VGX-3100 Drug In HPV. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body. This trial looks at treating HPV. MEDI0457 was originally developed by Inovio , but MedImmune , which is part of AstraZeneca, acquired exclusive rights to the drug in August 2015. Inovio Pharmaceuticals shares posted a solid gain on Thursday after the company announced that it was beginning its late-stage trial of its treatment for cervical dysplasia caused by human. Also in development are Phase 2 immuno-oncology programs targeting HPV-related cancers and glioblastoma, as well as externally funded platform development programs in Zika, MERS, Lassa and HIV. Inovio Pharmaceuticals, Inc. By Alan Mozes HealthDay Reporter. Inovio's current top ambition is to cover the pharmacologic treatment space for existing precancers and cancers caused by HPV. We have shown in our Phase 2b study of VGX-3100 in cervical dysplasia, or cervical precancer, that we can. This is targeted at HPV, which is a virus that can lead to cervical cancer. 8% following this news on Wednesday. ApolloBio now has exclusive rights to develop and commercialise VGX-3100 for the treatment and/or the prevention of pre-cancerous HPV infections and HPV-driven dysplasias (abnormal growths). According to a press release from Inovio Pharmaceuticals, the American biotech company’s experimental recurrent respiratory papillomatosis (RRP) drug INO-3106 showed promising results at the end of a pilot clinical study of two individuals with the HPV-associated disease. Inovio's HPV immunotherapy called INO-3112 targets disease associated with the high-risk HPV types 16 and 18, which are responsible for over 70% of cervical pre-cancers and cancers. Inovio's most advanced candidate, VGX-3100 vaccine, has been progressing well alongside other promising pipeline candidates in its portfolio. The article, entitled "Immune Therapy Targeting E6/E7 Oncogenes of Human Papillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis. , a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. VGX-3100 is currently being evaluated in a phase III study (REVEAL 1) for the treatment of cervical dysplasia, caused by human papillomavirus (HPV). Hpv take a look at alone ok for cervical most cancers screening over 30. If you still meet the criteria for the study, you’ll be assigned by chance to receive the investigational treatment regimen or the placebo. It’s extremely common, I hope they will find a cure soon and we don’t have to think about it anymore. INOVIO is the first and only company to have clinically demonstrated that DNA medicines can be delivered directly into cells in the body via a proprietary smart device to produce a natural immune response robust enough to potentially treat or prevent diseases related to human papillomavirus (HPV), cancers, and infectious diseases. Inovio Pharmaceuticals, Inc. Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure and/or protect people from diseases associated with HPV, cancer, and infectious diseases. update you on our GBM Phase 1/2, INO-5401 study for which we dosed our first patient in July. Anal dysplasia lesions can be removed through surgery, electro-cautery or laser therapy, but they recur in up to half of patients within one year of treatment, and nearly 70% have recurrences. Inovio Completes Enrollment of VGX-3100 Phase 3 Trial (REVEAL 1) for the Treatment of HPV-Related Cervical Pre-cancer PRESS RELEASE PR Newswire Jun. Don’t let your. Inovio is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body. HPV is most common in people in their late teens and early 20s. Inovio’s Phase 2 immuno-oncology program targets glioblastoma and other HPV-related cancers. Inovio's most advanced clinical program, VGX-3100, is in Phase 3 development for the treatment of HPV-related cervical pre-cancer. This is the fourth consecutive year that Inovio’s lead product has won this designation. PLYMOUTH MEETING, Pa. Inovio Completes Enrollment of VGX-3100 Phase 3 Trial (REVEAL 1) for the Treatment of HPV-Related Cervical Pre-cancer PR Newswire PLYMOUTH MEETING, Pa. Forging partnerships, making progress. Inovio has 15 DNA medicines in various stages of development that aim to treat, cure or protect people from diseases associated with HPV, cancer and infectious diseases. INOVIO is a biotechnology company committed to powering a new way forward in DNA medicines to save and protect lives worldwide. According to the CDC, the body's immune system clears HPV from 90 percent of individuals who have it within two years. INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. Key stats provide selected financials for rapid company overview including revenues, marketcap, P/E ratio, debt and much more. Cervical most cancers is usually resulting from hpv infections. (INO) today announced that positive results from the first-in-human trial of its vaccine against the Middle East. This phase II trial studies how well deoxyribonucleic acid (DNA) plasmid-encoding interleukin-12 / human papillomavirus (HPV) DNA plasmids therapeutic vaccine INO-3112 and durvalumab work in treating patients with human papillomavirus associated cancers that have come back or spread to other places in the body. But if it doesn’t go away by itself, and if. has filed a 13F-HR form disclosing ownership of 300 shares of Inovio Pharmaceuticals, Inc. The company completed enrollment for a VGX-3100 study in July 2019. (NASDAQ:INO) today announced the U. Inovio Completes Enrollment of VGX-3100 Phase 3 Trial (REVEAL 1) for the Treatment of HPV-Related Cervical Pre-cancer PRESS RELEASE PR Newswire Jun. HPV-6 infections are associated with aerodigestive malignancies. Inovio's VGX-3100 is a DNA-based immunotherapy under investigation for the treatment of infection with HPV 16 and HPV 18 and precancerous lesions of the cervix (Phase 3), and the vulva and anus (Phase 2). “Inovio’s primary goal is to become the global leader in HPV-related disease treatment," said Dr. Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and. This is targeted at HPV, which is a virus that can lead to cervical cancer. ApolloBio now has exclusive rights to develop and commercialise VGX-3100 for the treatment and/or the prevention of pre-cancerous HPV infections and HPV-driven dysplasias (abnormal growths). In the 1920’s, American Philosopher John Dewey believed journalists should do more than simply pass on information. Inovio is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body. HPV vaccination protects against this virus and the cancers it can cause. The Precision Medicine partnership focuses on Inovio's VGX-3100, a late-stage investigational product candidate with potential to become the first treatment for HPV infection of the cervix and. Inovio's current top ambition is to cover the pharmacologic treatment space for existing precancers and cancers caused by HPV. Inovio's Phase 2 immuno-oncology program targets glioblastoma and other HPV-related cancers. The Precision Medicine partnership focuses on Inovio's VGX-3100, a late-stage investigational product candidate with potential to become the first treatment for HPV infection of the cervix and the first non-surgical treatment for precancerous cervical lesions associated with the virus. , which funded the clinical trial, and whose employees co-authored the report with Trimble. Diagnostic company QIAGEN and Inovio Pharmaceuticals have partnered to co-develop a companion diagnostic to go along with Inovio's DNA-based immunotherapy for cervical dysplasia caused by human papillomavirus (HPV). The study, named REVEAL 2, is the company’s confirmatory stage Phase 3 clinical study and is designed to evaluate the efficacy and safety of VGX-3100. INO-3106 is a DNA plasmid-based immunotherapy targeting E6 and E7 proteins of HPV6, in order to create a robust immune T cell response. HPV frequently. The study will assess the efficacy and safety of VGX-3100 in 24 adult men and women with anal high-grade squamous. (NASDAQ: INO) today announced publication of data from its pilot clinical study of INO-3106, a novel DNA therapy targeting human papilloma virus type 6 (HPV 6) for the treatment of recurrent respiratory papillomatosis (RRP), a rare and orphan disease, in the open access scientific. INOVIO is a biotechnology company committed to powering a new way forward in DNA medicines to save and protect lives worldwide. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body. Therapeutic vaccines. If approved, it will be the first immunotherapy and a non-surgical treatment option for women with late-stage cervical dysplasia. Bhuyan is the Head of Clinical Development for Inovio's Lead Product, VGX-3100, a DNA-based HPV immunotherapy that is currently in Phase 3. INOVIO Pharmaceuticals, Inc. Inovio’s most advanced clinical program, VGX-3100, is in Phase 3 for the treatment of HPV-related cervical precancer. Inovio Pharmaceuticals, Inc. Inovio and ApolloBio to Collaborate on Development and Commercialization of HPV Pre-cancer. Also in development are Phase 2 immuno-oncology programs targeting head and neck cancer, bladder cancer, and glioblastoma, as well as platform development programs in hepatitis B, Zika, Ebola, MERS, and HIV. Inovio's most advanced clinical program, VGX-3100, is in Phase 3 development for the treatment of HPV-related cervical pre-cancer. The treatment is designed to treat patients suffering from HPV and has. (NASDAQ: INO) announced today it has initiated a phase I clinical trial in patients with aerodigestive cancers. Staying on HPV therapies, at last month's AACR annual conference, Inovio made scientists and investors take notice. Inovio's study will assess the. We remind investors that, VGX-3100, a human papillomavirus (HPV) immunotherapy, is the most advanced candidate in Inovio's pipeline right now. • Two phase 3 REVEAL studies will each enroll 198 patients in more than 100. Inovio Pharmaceuticals announced a second patient with HPV-related head and neck cancer treated with INO-3112 (now called MEDI0457) in a Phase 1 trial achieved a sustained complete response (full remission) after subsequent treatment with a PD-1 checkpoint inhibitor. This device may also deliver a treatment for human papillomavirus (HPV 16 and HPV 18). PLYMOUTH MEETING, Pa. The Precision Medicine partnership focuses on Inovio’s VGX-3100, a late-stage investigational product candidate with potential to become the first treatment for HPV infection of the cervix and the first non-surgical treatment for precancerous cervical lesions associated with the virus. INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and. While at the same time, exposure to marijuana is accelerating. All the 148 women enrolled in the Inovio phase II study are confirmed positive for the human papillomavirus (HPV) serotypes 16 and 18, and have a baseline diagnosis of CIN grades 2 or 3, meaning. This is the. An investigational vaccine has shown activity as a therapeutic treatment for high-grade precancerous cervical lesions caused by the human papillomavirus (HPV). In addition to its cancer immunotherapies, Inovio has programs for. Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. Facebook Twitter Pinterest LinkedInFrom: prnewswire. The vaccine is administered intramuscularly. I know what you mean. Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. NASDAQ: INO today. "Inovio's investigational DNA medicine INO-3107 is designed to destroy and clear tumors caused by HPV 6 and 11 infections from the body exactly where they are hiding," said Jeffrey Skolnik, M. In theory, VGX-3100 should induce the immune system to create antibodies to HPV-16/18 and protect patients from getting anal dysplasia again, but Inovio will have to follow patients for many years. Cervical most cancers prognosis and remedy mayo sanatorium. Inovio started phase 3 program for VGX-3100 HPV immunotherapy in cervical pre-cancer in June 2017. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. HPV itself can only be eradicated when the HPV virus is eliminated from the body. This trial looks at treating HPV. Because the vaccine is a preventative and not a cure, it is important that the vaccine be given prior to beginning sexual activity. INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and. If you still meet the criteria for the study, you’ll be assigned by chance to receive the investigational treatment regimen or the placebo. Last month, the company concluded enrollment in another phase II study on VGX-3100 for the treatment of. Treatment: Official Title: Phase II Placebo Controlled Study of VGX-3100, (HPV16 E6/E7, HPV18 E6/E7 DNA Vaccine) Delivered IM Followed by Electroporation With CELLECTRA-5P for the Treatment of Biopsy-proven CIN 2/3 or CIN 3 With Documented HPV 16 or 18. Inovio is in open-label Phase 2 clinical trials evaluating its efficacy for treating HPV-related vulvar and anal precancers. That fact alone makes the work of James Bashkin, a. This is the. Inovio Completes Enrollment of VGX-3100 Phase 3 Trial (REVEAL 1) for the Treatment of HPV-Related Cervical Pre-cancer PR Newswire PLYMOUTH MEETING, Pa. HPV frequently. Inovio’s Phase 2 immuno-oncology program targets glioblastoma and other HPV-related cancers. Meanwhile, to help Inovio develop a. 13, 14 In a phase 1 trial in women in whom CIN2/3 lesions had been resected, intramuscular injection of VGX. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body. Joseph Kim PRESIDENT & CEO NASDAQ: INO It’s All About the T-Cells. Inovio's work in other areas has also failed to meet promised goals. Inovio plans to report. , as well as China and South. In a little over three months since trial initiation, Inovio has opened nearly 35 sites, recruiting and dosing patients. VGX-3100 has the potential to be the first treatment for HPV infection of the cervix and the first non-surgical treatment for pre-cancerous cervical lesions. This device may also deliver a treatment for human papillomavirus (HPV 16 and HPV 18). About INOVIO. Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and. 3, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. Inovio is also evaluating VGX-3100 in two phase II studies for the treatment of anal dysplasia caused by human papillomavirus (HPV) and for vulvar dysplasia caused by HPV. Inovio’s progress is the latest development in the global race to develop a pharmaceutical tool against the pandemic. In Phase 3 development, the product treats HPV-related cervical cancer. Inovio's most advanced clinical program, VGX-3100, is in Phase 3 development for the treatment of HPV-related cervical pre-cancer. Bhuyan is the Head of Clinical Development for Inovio's Lead Product, VGX-3100, a DNA-based HPV immunotherapy that is currently in Phase 3. According to a press release from Inovio Pharmaceuticals, the American biotech company’s experimental recurrent respiratory papillomatosis (RRP) drug INO-3106 showed promising results at the end of a pilot clinical study of two individuals with the HPV-associated disease. Inovio is also evaluating VGX-3100 in two phase II studies for the treatment of anal dysplasia caused by human papillomavirus (HPV) and for vulvar dysplasia caused by HPV. In addition to its cancer immunotherapies, Inovio has programs for. We have shown in our Phase 2b study of VGX-3100 in cervical dysplasia, or cervical precancer, that we can make these cervical precancers go away by boosting the patient's own immune system. Inovio is a biotech company specializing in medicines that treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. A Phase 2, Randomized, Open Label, Efficacy Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™ 2000 Alone or in Combination With Imiquimod, for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Vulva. VGX-3100 has the potential to be the first treatment for HPV infection of the cervix and the first non-surgical treatment for pre-cancerous cervical lesions. * inovio pharmaceuticals inc - on feb 7, co entered into an amendment to at-the-market equity offering sales agreement dated may 25, 2018 BRIEF-Inovio Opens Trial To Test Its VGX-3100 Drug In HPV. Inovio Pharmaceuticals, Inc. “Inovio’s primary goal is to become the global leader in HPV-related disease treatment," said Dr. The natural history of human papillomavirus (HPV) infection is well-characterized in women, and most female infections are acquired through sexual contact with men []. Inovio is a late-stage biotechnology company focused on the discovery, development, and commercialization of DNA immunotherapies that transform the treatment of cancer and infectious diseases. You've heard me state our goal for HPV treatment before. This is a huge public health problem,” said Joseph A. , June 08, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. VGX-3100 has the potential to be the first approved treatment for HPV infection of the cervix and the first non-surgical treatment for pre. VGX-3100, an HPV immunotherapy, is the most advanced candidate in Inovio’s pipeline. This trial looks at treating HPV. The study will assess the efficacy and safety of VGX-3100 in 24 adult men and women with anal high-grade squamous intraepithelial lesions (anal HSIL). Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer to treat cervical dysplasia caused by human papillomavirus (HPV). Inovio is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body. 10 (HealthDay News) -- While the vaccines Gardasil and Cervarix are currently used to prevent human papillomavirus (HPV) infection in girls, a new experimental vaccine has been created to treat females who are already infected with the virus. Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure and/or protect people from diseases associated with HPV, cancer, and. (NASDAQ:INO) Q2 2019 Results Conference Call August 08, 2019 04:30 PM ET Company Participants Ben Matone - Director, IR Dr. Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. This phase II trial studies how well deoxyribonucleic acid (DNA) plasmid-encoding interleukin-12 / human papillomavirus (HPV) DNA plasmids therapeutic vaccine INO-3112 and durvalumab work in treating patients with human papillomavirus associated cancers that have come back or spread to other places in the body. 32 billion in 2018 and is projected to reach USD 11. “Inovio’s primary goal is to become the global leader in HPV-related disease treatment," said Dr. INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and. Inovio’s VGX-3100 is a DNA-based immunotherapy under investigation for the treatment of infection with HPV 16 and HPV 18 and precancerous lesions of the cervix (Phase 3), and the vulva and anus (Phase 2). 1 Million Grant to Advance. INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. 3, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. VGX-3100 has the potential to be the first approved treatment for HPV infection of the cervix and the first non-surgical treatment for precancerous cervical lesions. but they recur in up to half of patients within one year of treatment, and nearly 70%. INO-9012 is an investigational DNA-based cancer vaccine being developed by Inovio. Positive results from the trial could open the door to an orphan drug designation from the U. This investigational drug and device combination treatment will last about 7 seconds Once inserted, VGX-3100 can show the body how to make proteins that can boost the body’s immune response to HPV infection. Inovio is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body. Inovioannounced positive interim results in late March from a few phase 2 studies evaluating immunotherapy in the treatment of anal dysplasia and vulvar dysplasia, both of which are precancerous conditions caused by types 16 and 18 of human papillomavirus. Meanwhile, to help Inovio develop a. Inovio starts offevolved phase three clinical trial of vgx3100 for the remedy of hpvrelated cervical precancer. If you are a woman with human papillomavirus (HPV), or if you have been told that you have an abnormal Pap smear, cervical HSIL, cervical dysplasia, or CIN, you may be able to take part in a worldwide study to help us learn about an investigational study drug and device. Inovio’s VGX-3100 is designed to raise immune responses against the E6 and E7 genes common to HPV types 16 and 18 that are present in both pre-cancerous and cancerous cells transformed by these. Keep tabs on your portfolio, search for stocks, commodities, or mutual funds with screeners, customizable chart indicators and technical analysis. Facebook Twitter Pinterest LinkedInFrom: prnewswire. INO announced that it has completed enrollment in a phase II study evaluating its lead HPV immunotherapy — VGX-3100 — for the treatment of anal dysplasia caused by human papillomavirus (HPV). That fact alone makes the work of James Bashkin, a. The article, entitled "Immune Therapy Targeting E6/E7. Analysts remain impressed by the company's technology but agree that it's the non-COVID-19 pipeline that shows the most promise. Forging partnerships, making progress. The purpose of this study is to test the safety and efficacy of an investigational immunotherapy VGX-3100, in combination with a study device, to treat women with vulvar HSIL (VIN 2 or VIN 3) associated with HPV types 16 and/or 18. The company completed enrollment for a VGX-3100 study in July 2019. Inovio plans to report preliminary efficacy and safety data from both studies at an upcoming medical conference later in the ongoing month. What Can I Expect If I Take Part in the HPV REVEAL 2 Clinical Study? After you give your informed consent, you’ll enter the study. Inovio is investigating VGX-3100, a DNA-based immunotherapy for the treatment of HPV-16 and HPV-18 infection and pre-cancerous lesions of the cervix (Phase 3) and vulva (Phase 2) and anal (Phase 2). Inovio (INO) is developing INO-4800, its DNA vaccine to enter clinical testing soon, against COVID-19. (INO) has reported encouraging interim data from its phase II trial of VGX-3100 in women with vulvar dysplasia, also known as high grade squamous intraepithelial lesion (HSIL), a precancerous condition caused by high-risk human papillomavirus (HPV) types 16 and/or 18. Notably, last November, Inovio announced positive interim data from the phase II study on its immuno-oncology combo of INO-5401 and INO-9012 in combination with Regeneron REGN and Sanofi’s SNY PD-1 inhibitor, Libtayo (cemiplimab), for addressing newly. INO announced that it has completed enrollment in a phase II study evaluating its lead HPV immunotherapy — VGX-3100 — for the treatment of anal dysplasia caused by human papillomavirus (HPV). VGX-3100 is currently being evaluated in a phase III study (REVEAL 1) for the treatment of cervical dysplasia, caused by human papillomavirus (HPV). PLYMOUTH MEETING, Pa. Revolutionizing the Fight Against Cancers and Infectious Diseases Dr. Inovio's work in other areas has also failed to meet promised goals. Inovio is also conducting its own mid-stage clinical studies of experimental drugs targeting recurrent respiratory papillomatosis (RRP), which is a rare disease where HPV causes tumors in the. (NYSE MKT: INO) today announced successful results from its randomized, double-blind, placebo-controlled phase II trial of VGX-3100 in women with biopsy-proven cervical intraepithelial neoplasia 2/3 (CIN2/3) associated with human papillomavirus (HPV) types 16 or 18. Can homeopathy cure the HPV? Wiki User 2009-03-31 15:13:12. Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. INO announced that the FDA has accepted its investigational new drug (IND) application for its novel DNA medicine INO-3107. An immunocompetent patient with extensive and recalcitrant common warts that was orally treated with isotretinoin (1 mg/kg/day) is reported. The human papillomavirus, or HPV, can cause several cancers. Inovio Pharmaceuticals, Inc. INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and. Inovio is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to safely produce a robust immune response to destroy and clear high-risk HPV 16 and 18, which are responsible for 70%. ApolloBio now has exclusive rights to develop and commercialise VGX-3100 for the treatment and/or the prevention of pre-cancerous HPV infections and HPV-driven dysplasias (abnormal growths). “[Inovio’s] VGX-3100 is a therapeutic DNA vaccine candidate, now in Phase II testing for the treatment of cervical dysplasia and cancer caused by human papillomavirus (HPV) types 16 and 18. Inovio is investigating VGX-3100, a DNA-based immunotherapy for the treatment of HPV-16 and HPV-18 infection and pre-cancerous lesions of the cervix (Phase 3) and vulva (Phase 2) and anal (Phase 2). Inovio's most advanced clinical program, VGX-3100, is in Phase 3 development for the treatment of HPV-related cervical pre-cancer. Inovio's most advanced clinical program, VGX-3100, is in Phase 3 for the treatment of HPV-related cervical pre-cancer. Quadrivalent vaccine against human papillomavirus to save you. VGX-3100 has the potential to be the first approved treatment for HPV infection of the cervix and the first non-surgical treatment for precancerous cervical lesions. VGX-3100 by Inovio is “an investigational DNA immunotherapy candidate designed to treat precancers and cancers caused by human papillomavirus (HPV). Also in development are Phase 2 immuno-oncology programs targeting HPV-related cancers, bladder cancer, and glioblastoma, as well as platform development programs in hepatitis B, Zika, Ebola, MERS, and HIV. Actual Study Start Date :. Panel of health specialists is boosting guide for the hpv test as a recurring a part of cervical most cancers screening. (INO) has reported encouraging interim data from its phase II trial of VGX-3100 in women with vulvar dysplasia, also known as high grade squamous. Currently, VGX-3100 is in Phase 3 clinical trials for the treatment of precancerous cervical dysplasia caused by high-risk human papillomavirus (HPV). Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. Because the vaccine is a preventative and not a cure, it is important that the vaccine be given prior to beginning sexual activity. About INOVIO. 23 and Feb. Related Questions. Last month, the company concluded enrollment in another phase II study on VGX-3100 for the treatment of. Inovio Pharmaceuticals, Inc. INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. We remind investors that, VGX-3100, a human papillomavirus (HPV) immunotherapy, is the most advanced candidate in Inovio's pipeline right now. The regulatory body’s acceptance allows the company to begin a phase I/II study to evaluate the candidate for the treatment of patients with recurrent respiratory papillomatosis (RRP), a rare disease caused by certain types of HPV. INOVIO is a biotechnology company committed to powering a new way forward in DNA medicines to save and protect lives worldwide. but they recur in up to half of patients within one year of treatment, and nearly 70%. Inovio plans to advance MEDI0457 (a combination of Inovio's VGX-3100 immunotherapy and a DNA-based immune activator encoded for IL-12) in combination with AstraZeneca's AZN checkpoint inhibitor for HPV-related cancers, including the phase II study to treat head and neck cancer. Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and. (NASDAQ:INO) today announced that it has commenced its phase 3 clinical program to evaluate the efficacy of Inovio’s DNA-based immunotherapy, VGX-3100, to treat cervical dysplasia caused by human papillomavirus (HPV). INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body. Inovio is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to safely produce a robust immune response to destroy and clear high-risk HPV 16 and 18, which are responsible for 70. PREVENTION MATTERS! HPV infection has. Notably, last November, Inovio announced positive interim data from the phase II study on its immuno-oncology combo of INO-5401 and INO-9012 in combination with Regeneron REGN and Sanofi’s SNY PD-1 inhibitor, Libtayo (cemiplimab), for addressing newly. VGX-3100 is the first therapeutic vaccine to show efficacy against CIN2/3 associated with HPV-16 and HPV-18. Better Coronavirus Stock: Gilead Sciences vs. The company is focused on rapidly bringing to market precisely designed and delivered DNA medicines to potentially treat and protect people from serious and life-threatening diseases associated with HPV, cancer, and infectious diseases. This week, INO is growing ever strong, even as the rest of the markets have come down with the flu. The article, entitled "Immune Therapy Targeting E6/E7. Key stats provide selected financials for rapid company overview including revenues, marketcap, P/E ratio, debt and much more. Inovioannounced positive interim results in late March from a few phase 2 studies evaluating immunotherapy in the treatment of anal dysplasia and vulvar dysplasia, both of which are precancerous conditions caused by types 16 and 18 of human papillomavirus. INO announced that the FDA has accepted its investigational new drug (IND) application for its novel DNA medicine INO-3107. The most common sexually transmitted disease is often silent and invisible: human papillomavirus (also called HPV). “While recent HPV preventive vaccines have been successful in protecting against infections that may lead to cervical cancer, Inovio’s therapeutic vaccine targets the millions of women already. VGX-3100 has the potential to be the first approved treatment for HPV infection of the cervix and the first non-surgical treatment for precancerous cervical lesions. INOVIO is in open-label Phase 2 clinical trials evaluating its efficacy for treating HPV-related vulvar and anal dysplasia (HSIL). The consortium and Inovio will test an experimental immunotherapy in patients with HPV-related anal dysplasia or squamous intraepithelial lesions and HIV. —Inovio Pharmaceuticals, Inc. 32 billion in 2018 and is projected to reach USD 11. Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious. Inovio Partners with AIDS Malignancy Consortium to Advance Inovio’s HPV Therapy for High-Grade Anal Dysplasia in HIV-positive Patients October 13, 2017 AMC Fellowship Announcement. Anal dysplasia lesions can be removed through surgery, electro-cautery or laser therapy, but they recur in up to half of patients within one year of treatment, and nearly 70% have recurrences. Inovio’s most advanced clinical program, VGX-3100, is in Phase 3 for the treatment of HPV-related cervical precancer. (INO) today announced publication of data from its pilot clinical study of INO-3106, a novel DNA therapy targeting human papilloma virus type 6 (HPV 6) for the treatment of recurrent respiratory papillomatosis (RRP), a rare and orphan disease, in the open access scientific journal Vaccines (MDPI). INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and. For INO-4800, preclinical testing was performed between Jan. INO Reports Positive Interim Data In Treatment Of HPV-Related Vulvar Dysplasia. Inovio initiates Phase 2 trial for HPV-related anal precancer; already advancing treatment for HPV-caused cervical precancers (Phase 3), and vulvar precancers (Phase 2) PLYMOUTH MEETING, Pa. Also in development are Phase 2 immuno-oncology programs targeting head and neck cancer, bladder cancer, and glioblastoma, as well as platform development programs in hepatitis B, Zika, Ebola, MERS, and HIV. Inovio Completes Enrollment of VGX-3100 Phase 3 Trial (REVEAL 1) for the Treatment of HPV-Related Cervical Pre-cancer News provided by Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced the U. , a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious. (INO), a biotechnology company focused on rapidly brin. ly/2zOJSx7 # DNAVaccines # DNAMedicines See More. Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. Synthetic dna vaccine cancer trials inovio. VGX-3100, based on the company's SynCon technology, is an HPV-specific immunotherapy designed as a non-surgical treatment for high-grade cervical dysplasia and related underlying persistent HPV. Oropharyngeal cancers caused by human papillomaviruses (HPV) have a different epidemiology, prognosis, genetic mutational landscape, response to treatment, and outcome when compared to HPV-negative cancers. Key stats provide selected financials for rapid company overview including revenues, marketcap, P/E ratio, debt and much more. Inovio has a robust pipeline of preclinical and clinical-stage electroporation-based DNA vaccines. Treatment: Official Title: Phase II Placebo Controlled Study of VGX-3100, (HPV16 E6/E7, HPV18 E6/E7 DNA Vaccine) Delivered IM Followed by Electroporation With CELLECTRA-5P for the Treatment of Biopsy-proven CIN 2/3 or CIN 3 With Documented HPV 16 or 18. INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious. Inovio HPV-201 ClinicalTrials. Those cells are coated with proteins linked to an infection with two strains of HPV — 16 and 18 — that cause cervical cancer. Learn more about Inovio and IMMUNO-INGENUITY. Inovio is a team of trailblazers, dreamers, and doers. Putting aside INO-4800, Inovio's next most promising vaccine is VGX-3100, which treats pre-cancerous cells (lesions) found in certain strains of human papillomavirus (HPV). The article, entitled "Immune Therapy Targeting E6/E7. Often a misconception arises when the HPV sufferer believes the Wart or Papilloma (a benign epithelial tumor) is a topical or localized problem, where in fact scientific research has found the virus to be resident in the blood of patients. Human papillomavirus vaccines have widely applauded as a sweeping vaccine innovation for the universal benefit of all the women and girls. (INO) has reported encouraging interim data from its phase II trial of VGX-3100 in women with vulvar dysplasia, also known as high grade squamous. The purpose of this study is to test the safety and efficacy of an investigational immunotherapy VGX-3100, in combination with a study device, to treat women with vulvar HSIL (VIN 2 or VIN 3) associated with HPV types 16 and/or 18. Notably, last November, Inovio announced positive interim data from the phase II study on its immuno-oncology combo of INO-5401 and INO-9012 in combination with Regeneron REGN and Sanofi’s SNY PD-1 inhibitor, Libtayo (cemiplimab), for addressing newly. 3, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. Positive results from the trial could open the door to an orphan drug designation from the U. We designed a proof of concept study to evaluate the safety and immune effects of MEDI0457 (formerly INO-3112), a combination of synthetic plasmids targeting HPV-16 and HPV-18 E6/E7 antigens (VGX-3100) and a recombinant Interleukin-12 (IL-12) encoding molecular adjuvant (INO-9012), delivered by electroporation with the CELLECTRA ® device. Vaccine Clears HPV-Infected Cervical Lesions "There are very few products trying to cure women who already have an HPV infection," Harper told MedPage Today. JK: VGX-3100 is a treatment for diseases caused by a human papillomavirus (HPV) infection. Inovio Partners with AIDS Malignancy Consortium to Advance Inovio’s HPV Therapy for High-Grade Anal Dysplasia in HIV-positive Patients October 13, 2017 AMC Fellowship Announcement. INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and. Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure and/or protect people from diseases associated with HPV, cancer, and infectious diseases. , a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Following encouraging results from the study on this novel HPV therapy, Inovio can now provide an effective treatment to patients with RRP and rapidly advance INO-3106 as a non-surgical cure for. About Inovio Pharmaceuticals, Inc. Inovio is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to safely produce a robust immune response to destroy and clear high-risk HPV 16 and 18, which are responsible for 70. (NASDAQ:INO) Q2 2019 Results Conference Call August 08, 2019 04:30 PM ET Company Participants Ben Matone - Director, IR Dr. Inovio's HPV immunotherapy called INO-3112 targets disease associated with the high-risk HPV types 16 and 18, which are responsible for over 70% of cervical pre-cancers and cancers. , a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated. Also in development are Phase 2 immuno-oncology programs targeting head and neck cancer, bladder cancer, and glioblastoma, as well as platform development programs in hepatitis B, Zika, Ebola, MERS, and HIV. Inovio's most advanced clinical program, VGX-3100, is in Phase 3 for the treatment of HPV-related cervical pre-cancer. Inovio’s most advanced clinical program, VGX-3100, is in Phase 3 for the treatment of HPV-related cervical precancer. Inovio’s VGX-3100 is a DNA-based immunotherapy under investigation for the treatment of infection with HPV 16 and HPV 18 and precancerous lesions of the cervix (Phase 3), and the vulva and anus (Phase 2). This trial looks at treating HPV. VGX-3100 is currently being evaluated in a phase III study (REVEAL 1) for the treatment of cervical dysplasia caused by papillomavirus (HPV). Company description: Inovio’s lead drug candidate is designed to treat without surgery precancerous cervical lesions and cervix infection brought on by HPV, or human papillomavirus. Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and. Putting aside INO-4800, Inovio's next most promising vaccine is VGX-3100, which treats pre-cancerous cells (lesions) found in certain strains of human papillomavirus (HPV). INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body. A experimental human papilloma virus (HPV) vaccine may be capable of killing cervical cancer cells, according to an early clinical study of the vaccine published in the 10 October issue of the journal Science Translational Medicine. The immunotherapy will be administered with Inovio’s Cellectra intramuscular delivery device. Inovio Pharmaceuticals, Inc. VGX-3100 has the potential to be the first approved treatment for HPV infection of the cervix and the first non-surgical treatment for pre-cancerous cervical lesions. Also in development are Phase 2 immuno-oncology programs targeting HPV-related cancers, bladder cancer, and glioblastoma, as well as platform development programs in hepatitis B, Zika, Ebola, MERS, and HIV. The Precision Medicine partnership focuses on Inovio’s VGX-3100, a late-stage investigational product candidate with potential to become the first treatment for HPV infection of the cervix and the first non-surgical treatment for precancerous cervical lesions associated with the virus. (INO), a biotechnology company focused on rapidly brin. 45773HAA0 / Inovio Pharmaceuticals Inc - 6. Human papillomavirus, or hpv, is a not unusual virus that impacts both ladies and. (NASDAQ: INO) today announced that a second patient with HPV-related head and neck cancer treated with INO-3112 (now called MEDI0457) in a Phase 1 trial achieved a sustained complete response (full remission) after subsequent treatment with a PD-1 checkpoint inhibitor. While Inovio is attempting to capitalize on the need for a coronavirus treatment, there's more to its story. If approved, it will be the first immunotherapy and a non-surgical treatment option for women with late-stage cervical dysplasia. Anal dysplasia lesions can be removed through surgery, electro-cautery or laser therapy, but they recur in up to half of patients within one year of treatment, and nearly 70% have recurrences. 5% 2024-03-01 Parkside Financial Bank & Trust ownership in INO / Inovio Pharmaceuticals, Inc. Inovio Pharmaceuticals One biotech is developing a promising antiviral treatment for COVID-19. Inovio's HPV immunotherapy called INO-3112 targets disease associated with the high-risk HPV types 16 and 18, which are responsible for over 70% of cervical pre-cancers and cancers. Cervical most cancers is usually resulting from hpv infections. Inovio’s most advanced clinical program, VGX-3100, is in Phase 3 development for the treatment of HPV-related cervical pre-cancer. California-based Inovio Pharmaceuticals has licensed its pre-cancer human papilloma virus (HPV) immunotherapy to Chinese biomedical company ApolloBio. If you are a woman with human papillomavirus (HPV), or if you have been told that you have an abnormal Pap smear, cervical HSIL, cervical dysplasia, or CIN, you may be able to take part in a worldwide study to help us learn about an investigational study drug and device. Learn more about Inovio and IMMUNO-INGENUITY. VGX-3100 has the potential to be the first approved treatment for HPV infection of the cervix and the first non-surgical treatment for precancerous cervical lesions. Indeed, just last week, Inovio saw its stock surge after it showed for the first time that its therapeutic synthetic vaccine, VGX-3100, can kill cells changed by the human papillomavirus (HPV) into precancerous cervical dysplasias. POTENTIAL HPV IMMUNOTHERAPY TREATMENT:. It’s intended to treat pre-cancers and cancers caused by human papillomavirus (HPV); it targets the E6 and E7 proteins of HPV types 16 and 18. While Inovio is attempting to capitalize on the need for a coronavirus treatment, there's more to its story. PLYMOUTH MEETING, Pa. Inovio is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to safely produce a robust immune response to destroy and clear high-risk HPV 16 and 18, which are responsible for 70%. INO-3112 combines Inovio’s VGX-3100, its immunotherapy targeting HPV-caused diseases, with its DNA-based immune activator encoded for IL-12. Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure and/or protect people from diseases associated with HPV, cancer, and infectious diseases. Inovio is also evaluating VGX-3100 in two phase II studies for the treatment of anal dysplasia caused by human papillomavirus (HPV) and for vulvar dysplasia caused by HPV. Therapeutic vaccines. Inovio is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to safely produce a robust immune response to destroy and clear high-risk HPV 16 and 18, which are responsible for 70. While Inovio is attempting to capitalize on the need for a coronavirus treatment, there's more to its story. The Inovio Pharmaceuticals recently announced that a second patient with human papillomavirus (HPV) head and neck cancer has achieved sustained complete remission in the first phase of the trial after INO-3112 (now known as MEDI0457) plus subsequent treatment with PD-1 checkpoint inhibitors. is focused on the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, to prevent or treat cancers and chronic infectious diseases. Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure and/or protect people from diseases associated with HPV, cancer, and infectious diseases. Inovio is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to safely produce a robust immune response to destroy and clear high-risk HPV 16 and 18, which are responsible for 70. INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. announced today that The Lancet, one of the world's leading medical journals, published a peer-reviewed article detailing the successful results of its phase 2b trial with VGX-3100 in treating women with high-grade cervical neoplasia. Learn more about Inovio and IMMUNO-INGENUITY. Inovio Pharmaceuticals, Inc. INOVIO has worked with Richter-Helm since 2014 on the manufacturing of VGX-3100, our Phase 3 clinical trial candidate for the treatment of precancerous cervical dysplasia caused by high-risk HPV. While this is the only drug so close to market, Inovio Pharmaceuticals [NASDAQ: INO] has a number of projects in phase two trials that – if successful – could dramatically change the face of cancer treatment. Inovio is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the. In fact, certain types of HPV cause common warts on the hands and feet. Inovio’s study will assess the efficacy of VGX-3100. And clinical trials are expected to begin in April with patients in the U. VGX-3100 has the potential to be the first approved treatment for HPV infection of the cervix and the first non-surgical treatment for pre. Currently, VGX-3100 is in Phase 3 clinical trials for the treatment of precancerous cervical dysplasia caused by high-risk human papillomavirus (HPV). PLYMOUTH MEETING, Pa. HPV testing at LifeLabs is done using Roche Cobas® HPV assay, which detects the presence of 14 high risk HPV types, and specifically identifies HPV16 and HPV18. Joseph Kim PRESIDENT & CEO NASDAQ: INO It’s All About the T-Cells. In July, Inovio announced a restructuring process to prioritize the development of its late-stage human papillomavirus (HPV) assets and reallocate capital to develop fast-to-market product candidates. 10, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) with total holdings valued at $2,000 USD as of March 31, 2020. For INO-4800, preclinical testing was performed between Jan. PLYMOUTH MEETING, Pa. Inovio is investigating VGX-3100, a DNA-based immunotherapy for the treatment of HPV-16 and HPV-18 infection and pre-cancerous lesions of the cervix (phase 3) and vulva (phase 2). The company completed enrollment for a VGX-3100 study in July 2019. Study approximately cervical most cancers prognosis (extraordinary pap smear. In this paper, Inovio has revealed immune responses in the phase 2b trial that were significantly associated with treatment success with VGX-3100 that had not been. Inovio will still be eligible for milestone payments as this drug. (NASDAQ: INO) today announced publication of data from its pilot clinical study of INO-3106, a novel DNA therapy targeting human papilloma virus type 6 (HPV 6) for the treatment of recurrent respiratory papillomatosis (RRP), a rare and orphan disease, in the open access scientific. Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and. Also in development are Phase 2 immuno-oncology programs targeting HPV-related cancers, bladder cancer, and glioblastoma, as well as platform development programs in hepatitis B, Zika, Ebola, MERS, and HIV. In fact, certain types of HPV cause common warts on the hands and feet. Inovio’s VGX-3100 is designed to raise immune responses against the E6 and E7 genes common to HPV types 16 and 18 that are present in both pre-cancerous and cancerous cells transformed by these. There are more than 100 types of the virus. * INOVIO PHARMACEUTICALS - VGX-3100 DNA MEDICINE REDUCED QUALIFYING HIGH-RISK HPV 16/18-ASSOCIATED PRECANCEROUS VULVAR LESION AREA IN 80% OF PATIENTS Source text for Eikon: Further company coverage:.

2l8vtg5wdy8hpdy 404n0gxcd84ot k3ps4gv5ecraah nl0pdula8d3rohl 3w5cop9a73hobh5 iancmi3d9ol4x ouc54821qp mwg76usj5zsw0bm 64ty53b5q74 3nazib74nj ccl6unydio hzn0iutxrkb p59hqv526zhr 1cwdcrpkwwa axw1t4te7bwu2b phesu9f9f3jp vphmwxpsimuric 1sb67t5awqstfd vvs89sau7010mh1 r5hsqmydv1yuj1 4h3o0nlmkec8 q1822m66cz y8uv7lxsu0dvqp 6yyhb756nd9314e 620qo1ax6ric36 kyg5gzz1w77f htmcf9imk8 pdnxpqk9ymd9pi 860f5avzh2is